New Approaches Targeting Androgen Receptor Signal Pathways for Treatment of Castration-Resistant Prostate Cancer

QR Code

New Approaches Targeting Androgen Receptor Signal Pathways for Treatment of Castration-Resistant Prostate Cancer

None

Saved in:

Bibliographic Details
Main Authors:	Donkena, Young
Format:	Electronic Book Chapter
Language:	English
Published:	IntechOpen 2011
Subjects:	Health Sciences
Online Access:	https://www.intechopen.com/chapters/24585
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies
by: Quistini A, et al.
Published: (2025-06-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
by: Shawn Du, et al.
Published: (2025-07-01)

Intermittent androgen therapy in prostate cancer reveals the pro-apoptotic roles of androgen/androgen receptor: an overview
by: Saleh Altuwaijri, et al.
Published: (2025-03-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Prenylated Chalcones as Anticancer Agents Against Castration-Resistant Prostate Cancer
by: Marcos Morales-Reyna, et al.
Published: (2025-06-01)

Inhibition of Advanced Prostate Cancer by Androgens and Liver X Receptor Agonists
by: Chuu, Chih-Pin, et al.
Published: (2011)

Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives
by: Jieping Hu, et al.
Published: (2017-04-01)

Synergistic anticancer effect of CDRI-08 and Abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway
by: Bhavana Jonnalagadda, et al.
Published: (2025-09-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01)

Therapy results of patients with metastatic castration‑resistant prostate cancer. Regional experience
by: P. G. Berezin, et al.
Published: (2023-03-01)

ROLE OF NEUREGULINS AND HEPATOCYTE GROWTH FACTOR IN THE DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: L. V. Spirina, et al.
Published: (2016-02-01)

Androgen Deprivation Therapy for Prostate Cancer
by: Ziaran, Stanislav
Published: (2011)

Current Options and Future Directions in Castrate Resistant Prostate (CRPC)
by: Richter, Suzanne, et al.
Published: (2011)

Visualizing androgen signaling and assessing its interaction with canonical Wnt signaling pathways in prostate development, morphogenesis, and regeneration.
by: Yao Mawulikplimi Adzavon, et al.
Published: (2025-06-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

CAF-mediated regulation of prostate cancer stem cell stemness via the Wnt/β-catenin and SDF-1/CXCR4 pathways in castration-resistant prostate cancer
by: Haoran Chen, et al.
Published: (2025-07-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Prostate Cancer Progression to Androgen Independent Disease: The Role of the Wnt/β-Catenin Pathway
by: Ha, Jacqueline R., et al.
Published: (2011)

THERAPY WITH SOMATOSTATIN ANALOGUES IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: K. Y. Kanukoev, et al.
Published: (2015-04-01)

Structural Retinal and Optic Nerve Changes in Prostate Cancer Patients Receiving Androgen Receptor Pathway Inhibitors: An OCT-Based In Vivo Analysis
by: Yasemin Bakkal Temi, et al.
Published: (2025-07-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

Stem Like Cells and Androgen Deprivation in Prostate Cancer
by: Tang, Yao, et al.
Published: (2011)

PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES
by: K. M. Nushko, et al.
Published: (2015-10-01)

<sup>225</sup>Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer
by: T. Yu. Kochetova, et al.
Published: (2025-01-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
by: Y. Inoue, et al.
Published: (2025-07-01)

Signalling Pathways and Gene Expression Profiles in Prostate Cancer
by: Marsella-Hatziieremia, Sophia, et al.
Published: (2011)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
by: O. I. Kit, et al.
Published: (2024-12-01)

BISPHOSPHONATES IN PROPHYLAXIS OF SKELETAL-RELATED ADVERSE EVENTS IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: E. Yu. Safronova, et al.
Published: (2016-06-01)

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients
by: Richell Booijink, et al.
Published: (2025-07-01)

Hedgehog signaling pathway as a potential target in the treatment of advanced gastric cancer
by: Dae-Hee Lee, et al.
Published: (2017-05-01)

Identification of Androgen Receptor as a Molecular Docking Target for Survival and Response to Metformin‐Induced Ferroptosis in Liver Cancer
by: Bin Zhang, et al.
Published: (2025-07-01)

Skeletal Scintigraphy in Assesing the Response of Prostate Cancer Metastases to Androgen Deprivation Therapy
by: S. P. Mironov, et al.
Published: (2021-09-01)

Influence of obesity and androgen deficiency on prostatic blood circulation
by: I. A. Tyuzikov, et al.
Published: (2012-04-01)

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis
by: Mingjun Rui, et al.
Published: (2025-07-01)

HIF1α-PHD1-FOXA1 Axis Orchestrates Hypoxic Reprogramming and Androgen Signaling Suppression in Prostate Cancer
by: Limiao Liang, et al.
Published: (2025-07-01)